DFDA

Brimonidine (topical)

Treatment for Rosacea

Typical Dosage: Pea-sized amount once daily

Effectiveness
60%
Safety Score
78%
Clinical Trials
9
Participants
2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
78
DangerousModerateSafe
Treatment Details
Dosage Range
Pea-sized amount once daily
Time to Effect
Within 30 minutes
Treatment Duration
Daily, as needed
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,500
Monitoring:$300
Side Effect Mgmt:$200
Total Annual:$3,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$18,487/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$4,615
Comparison vs Topical Oxymetazoline
Cost Difference
$-200/year
Less expensive
QALY Difference
-0.01 QALYs
Worse outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$2,150
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$80/year
Prior auth, claims
Rx Price
$2,500/year
Potential OTC Price
$800/year
Estimated if OTC available
Risk Assessment
Misuse Risk
MODERATE
Missed Diagnosis Risk
LOW
Brimonidine (topical) Outcomes

for Rosacea

Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+65%
Common Side Effects
Rebound erythema
+10%
Flushing
+5%
Burning/pruritus
+3%

Sources:

dermnetnz.org
nih.gov
ahdbonline.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
8 completed trials for Brimonidine (topical) in Rosacea

Internet Surveys and Their Impact on Adherence for Rosacea

NCT03048058COMPLETEDPHASE4
View Study
20 participants
INTERVENTIONAL
Winston-Salem, United States
Started: May 5, 2016

Mirvaso in Use Study

NCT02249065COMPLETEDPHASE4
View Study
205 participants
INTERVENTIONAL
Fort Smith, United States +11 more
Started: Sep 1, 2014

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

NCT02289352COMPLETEDPHASE3
View Study
462 participants
INTERVENTIONAL
Hot Springs, United States +15 more
Started: Jul 1, 2014

Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea

NCT02385240COMPLETEDPHASE3
View Study
552 participants
INTERVENTIONAL
Started: Mar 1, 2015

Brimonidine 0.33% for Rosacea-Related Facial Erythema

NCT07431476COMPLETEDPHASE4
View Study
45 participants
INTERVENTIONAL
Istanbul, Turkey (Türkiye)
Started: May 1, 2025

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250COMPLETEDPHASE4
View Study
190 participants
INTERVENTIONAL
Fort Smith, United States +12 more
Started: Dec 1, 2015

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

NCT01659853COMPLETEDPHASE3
View Study
70 participants
INTERVENTIONAL
Evansville, United States +3 more
Started: Sep 1, 2012

Preferences & Treatment Satisfaction Drivers in Rosacea Patients

NCT02602470COMPLETED
View Study
206 participants
OBSERVATIONAL
Boston, United States
Started: Jan 8, 2015